Description

Retatrutide, CAS number 2381089-83-2

Retatrutide is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). LY3437943 inhibits for human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. LY3437943 can be used for the research of obesity

I. Product Features

1. Cutting - edge R & D Process

After years of scientific research and development, we have utilized advanced biotechnologies and synthetic processes. This ensures that Retatrutide has an ultra - high purity, with the content of active ingredients far exceeding the industry average. Thanks to its precisely designed molecular structure, the product is highly stable and can maintain excellent activity under different storage conditions, laying a solid foundation for subsequent production and processing.

0. Unique Mechanism of Action

Retatrutide targets [EC50 (for human): 5.79 (GCGR), 0.0643 (GIPR), 0.775 nM (GLP-1R) [1]. EC50 (for mouse): 2.32 (GCGR), 0.191 (GIPR), 0.794 nM (GLP-1R) [1]. Ki (for human): 5.6 (GCGR), 0.057 (GIPR), 7.2 nM (GLP-1R) [1]. Ki (for mouse): 73 (GCGR), 2.8 (GIPR), 1.3 nM (GLP-1R)]. providing a powerful tool for pharmaceutical R & D and life science research.

II. Application Scenarios

1. Pharmaceutical R & D Field

As a core raw material for innovative drug development, Retatrutide can assist pharmaceutical companies in developing new therapeutic drugs for obesity. Its unique biological activity can accelerate the drug R & D process, improve R & D efficiency, and provide new solutions for conquering difficult diseases.

0. Scientific Research Experiment Scenarios

In life science research, Retatrutide is an essential research tool. Scientists use it to deeply explore methods, providing key data support for basic research and clinical application research, and promoting the transformation of scientific research achievements.